Cellectar Biosciences Inc. (NASDAQ:CLRB)
Bands
Volume
200 SMA
50 SMA
20 SMA
Videos
Alerts
Articles
Events
Old Forum Content for CLRB
Make a Forum Post Become a member to view recent forum posts. Already a member? Sign in here.
- sierramp: $CLRB Is in a nice basing pattern and they have funds from this news. The Tranche A warrants issued as part of the private placement announced in September 2023 have been exercised in full. All participants in the previous financing, led by Rosalind ...
- woodman: @sierramp $CLRB - I'm still holding a position in this one. I added a wee bit yesterday at 3.42.
- Onthemark: @sierramp $CLRB I am also holding a position, but expected this to be trading a bit higher instead of testing support.
- woodman: @Onthemark $CLRB - Seems okay on the chart. It's drifting into the rising 20d area which has been decent support of late and still holding the most recent range starting on 1/9.
- Onthemark: @woodman $CLRB Yes, today's low came within .07 cents of the 21dema, and now shows a bit of strength.
- sierramp: @woodman $CLRB I added a bit this morning at 3.3835. I see the bottom of this basing pattern near the MVWAP30 and 1-11 LOD. I like your observation that the 21D is close to meeting up with the aforementioned as well.
- MongosPawn: $CLRB Added.
- MongosPawn: $CLRB Some volume coming in. May be starting a phase 3 move.
- woodman: @MongosPawn $CLRB - Good eye. I looked at that flag this morning, but hadn't looked back since. I still have a position to which I want to add. Their data were great and the post-reporting PTs reflect it. They use targeted alpha therapy to treat blood cancers and solid tumors. From what I can tell, they may becoming a leader in the field. Ladenburg PT $13 (1/10). Oppenheimber up to $11 (1/9) from $8.
- sierramp: @MongosPawn $CLRB They announced promising preclinical data this morning. You and @Woodman have me interested in this. https://investor.cellectar.com/press-releases/detail/323/cellectar-biosciences-broadens-pipeline-with
- woodman: @sierramp $CLRB - Thanks. I hadn't seen that news.
- woodman: $CLRB nice dip to test yesterday's intraday low following the Biotech Showcase last night. Recovering now.
- woodman: $CLRB - And Ladenburg gave this a $13 PT. It loves the recent data, fwiw.
- MongosPawn: $CLRB Added small.
- Lou: @woodman $CLRB - I held on to my as well. Not a very big position.
- woodman: $CLRB - wow, still going. I sold almost all of my shares yesterday. I actually meant to sell all, and thought I did, but it turns out I still had some in one of my IRAs. I'm like a squirrel with nuts hidden all around. Still holding those shares.
- woodman: @Lou $CLRB - "hidded" = hidden. My fast typing has become absolutely awful.
- woodman: @chrisbman360 $EFTR - yes, the reverse split prior to coming data took everyone by surprise. It will be a very small float now. But I'm guessing, maybe, they need to be above certain price by a certain time for Nasdaq listing purposes , and I hope this helps in terms of institutions looking at it. It seems odd that they announced today that they are hosting an Investor Day on 1/24 to discuss data and milestones and the same day (today) announce the reverse split. Would the data, etc., be bad if they intend to host an Investor Day to talk about it? We can only speculate. Stay tuned for further tea leaves from the company. Tea leaf reading worked for $CLRB and its data yesterday. ($CLRB, btw, has a Biotech Showcase today at 5PM ET.)
- woodman: $CLRB I may have to buy back the shares I sold yesterday. It has Biotech Showcase presentation today (5PM ET). Oppenheimer has moved its PT to $11 from $8. "These go to 11." https://www.youtube.com/watch?v=KOO5S4vxi0o
- kenb: @woodman $CLRB no position. HOD appears to be $3.70 and watching for a pullback to some type of support for an entry.
- Lou: @kenb $CLRB - added twice today. Last at 3.68. Still in the green overall as it trades at 3.55.
- woodman: @Lou $CLRB - I sold most of mine at 3.40 avg yesterday. Watching now.
- kenb: @woodman $CLRB LOL on the video. Kind of describes what analysts do.
- woodman: @kenb $CLRB - That's funny!!
- sierramp: @woodman $CLRB That made me laugh. After we had debit card fraud a friend in a high profile fraud unit told me how to use multiple accounts to keep money separate and not all of it exposed to fraud in one account. I feel the same way with savings, checking and brokerage accounts now.
- woodman: @Lou $CLRB - Bought back @ $3.66 some of what I sold lower yesterday. Had to pick up my daughter and missed the drop into the $3.50s. Barely made it back in time to buy.
- woodman: $CLRB - homerun Phase 3 WM data reported. I held my shares through and I haven't sold yet. While it's up in the pre, oridinarily I'd expect it to be up more on this data. Unfortunately, I think the fear of a secondary and the warrants are a short term weight on price. Longer term, seems likely to go higher. Not sure yet what I will do with my shares today. Monitoring and trying to read up.
- wijimmy: @woodman $CLRB....@WOODMAN ... WOODY come on man $AMAM ... how did this one sneak by you ?? { HAHAHA }
- MongosPawn: @woodman $CLRB Added.
- woodman: @wijimmy $CLRB $AMAM - Dayum! JPM kicked-off with a bunch of acquisitions by $JNJ, $NVS, $MRK. Good way to kick off 2024. Good sign for biotech.
- woodman: @woodman $CLRB $AMAM $JNJ $NVS $MRK o $HARP acquired by $MRK. Big move.
- woodman: $CLRB - I sold this. It could go higher after providing additional info tomorrow at a Biotech Showcase conference (5pm ET tomorrow), but I've decided to go to the sideline with the $$. I do wonder if a secondary is coming. If so, I suppose I could bu ...
- woodman: $CLRB update - It will have a call to detail top-line WM data on 1/8 bmo, then present that data at the Biotech Showcase Conference (not JPM) the next day. https://www.cellectar.com/news-media/press-releases/detail/319/cellectar-biosciences-to-announce-top-line-data-from-wm
- Margi1983: @woodman $CLRB Thanks for the update. Long with modest position. You really know your biotech stuff. These others are not really biotech but I am also long $VRTX, $LLY, $NVO, and $PFE in the pharma space
- woodman: @Margi1983 $CLRB $VRTX $LLY $NVO $PFE - I won't hold all my shares through, but I still need to decide how much I will hold through. It's risky for sure. I can't imagine the company would be promoting this data so much into the presentation(s), but crazy stuff happens in BioLand. It could be a disappointment even if "good" or just simply an immediate sell the news. One never knows.
- woodman: $CLRB running into data reporting expected the week of Jan. 8. for its open label late stage pivitol data for lopofosine radioisotope CLR131 for Waldenstrom Macroglobulinemia (WM). Two ways to play: 1) this run into the data and get out before it is ...
- woodman: #Biotechs I'm focusing on (mostly for at least Q1/H1 2024) (in no particular order): $ARDX (I plan to contnue holding this through full year 2024) $EFTR $XFOR $VKTX $MREO (good buyout potential) $PDSB $INZY $CLRB (mainly for 1/8 data to be presented at JPM Healthcare Conf). Possibly some others as well such as $ORIC (I've lost focus on it and need to reacquaint myself) and $ACAD.
- woodman: $CLRB - added ahead of JPM healthcare conference the week of 1/8 where it will present Phase 3 data for its WM treatment. https://www.cellectar.com/news-media/press-releases/detail/315/cellectar-to-release-top-line-data-from-wm-pivotal-trial
- woodman: $CLRB on the rise into JPM Healthcare Conf. occuring week of 1/8/24. I have a position in this (bought ~$2.50). Why would it be presenting if the data aren't good? Lots of positives in this one reading other tea leaves as well. Could be a big mover on good data, but there never are guarantees. A bit of a lotto ticket. https://www.cellectar.com/news-media/press-releases/detail/315/cellectar-to-release-top-line-data-from-wm-pivotal-trial
- woodman: $CLRB - At the JPM HC conference on 1/8, this one will be presenting open label late stage pivotal data for its drug to treat Waldenstrom macroglobulinemia (WM). The question is why would this present at a prestigious health care conference if the data were bad? It's a gamble, but I bought some. Small position, though I may add to it in the interim. https://www.cellectar.com/product-pipeline
| Stock Price | $3.06 |
| Change | -1.61% |
| Volume | 1,043,210 |
Cellectar Biosciences Inc is a biopharmaceutical company. It is engaged in developing compounds for treatment and imaging of cancer. Its portfolio consists of PET imaging agents, optical imaging agents, and therapeutic agents.
Request Video of CLRBAlready a member? Sign in here.
Past Month
Leading Peers
-
$6.35 284.27%
-
$12.29 280.99%
-
$7.42 262.04%
Past Month
Lagging Peers
-
$27.30 -79.24%
-
$6.58 -66.46%
-
$14.27 -57.62%
Dan Fitzpatrick
Stock Market Mentor gives you EVERYTHING you need to succeed in the market; all in one place. How easy is that? Dan Fitzpatrick and his elite community of traders share trading ideas, strategies and much more. Dan Fitzpatrick--a world class Technical Analyst, trading coach and regular CNBC contributor--gives you access to all of this with a 30 day trial membership for just $7.77. Get started TODAY and start trading better TOMORROW with the following premium content:
- Nightly video Strategy Sessions with a game plan for tomorrow
- Got a stock you want Dan to look at? Just ask.
- Patent pending video alerts instantly delivered to you when one of Dan’s trading signals is triggered. This is not your typical price alert. This is a short video explaining the action you need to take to make money. No more “Woulda, coulda, shoulda”
- Access to over 90,400 stock analysis videos
- Access an ever expanding library (90,400) of educational videos that will save you time and make you money
Join a team of friends and traders that have one thing in common; a burning desire to succeed.
Become a Member Today!
Gain immediate access to all our exclusive articles, features, how-to's, discussion group and much more...
Satisfaction Guaranteed!
Your Stock Market Mentor membership comes with a 30 day, no questions asked, 100% money back guarantee!